These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 27468060)

  • 1. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
    Kühnen P; Clément K; Wiegand S; Blankenstein O; Gottesdiener K; Martini LL; Mai K; Blume-Peytavi U; Grüters A; Krude H
    N Engl J Med; 2016 Jul; 375(3):240-6. PubMed ID: 27468060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone-Replacement Therapy for Melanocyte-Stimulating Hormone Deficiency.
    Reitman ML
    N Engl J Med; 2016 Jul; 375(3):278-9. PubMed ID: 27468065
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
    Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
    Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mutation in the proopiomelanocortin (POMC) gene of a Hispanic child: metformin treatment shows a beneficial impact on the body mass index.
    Hilado MA; Randhawa RS
    J Pediatr Endocrinol Metab; 2018 Jul; 31(7):815-819. PubMed ID: 29858905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and Hyperphagia With Increased Defective ACTH: A Novel POMC Variant.
    van der Valk ES; Kleinendorst L; Delhanty PJD; van der Voorn B; Visser JA; van Haelst MM; de Graaff LCG; Huisman M; White A; Ito S; Wakamatsu K; de Rijke YB; van den Akker ELT; Iyer AM; van Rossum EFC
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3699-e3704. PubMed ID: 35737586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies.
    Wabitsch M; Fehnel S; Mallya UG; Sluga-O'Callaghan M; Richardson D; Price M; Kühnen P
    Adv Ther; 2022 Apr; 39(4):1772-1783. PubMed ID: 35192151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Cases With an Early Presented Proopiomelanocortin Deficiency-A Long-Term Follow-Up and Systematic Literature Review.
    Gregoric N; Groselj U; Bratina N; Debeljak M; Zerjav Tansek M; Suput Omladic J; Kovac J; Battelino T; Kotnik P; Avbelj Stefanija M
    Front Endocrinol (Lausanne); 2021; 12():689387. PubMed ID: 34177811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-opiomelanocortin (POMC) deficiency and peripheral melanocortins in obesity.
    Zemel MB; Shi H
    Nutr Rev; 2000 Jun; 58(6):177-80. PubMed ID: 10885325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin.
    Yaswen L; Diehl N; Brennan MB; Hochgeschwender U
    Nat Med; 1999 Sep; 5(9):1066-70. PubMed ID: 10470087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10.
    Krude H; Biebermann H; Schnabel D; Tansek MZ; Theunissen P; Mullis PE; Grüters A
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4633-40. PubMed ID: 14557433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
    Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Strategies Against Metabolic Imbalance in a Male Mouse Model With 5-HT2CR Loss-of-Function.
    Liu H; Liu Z; Wong HK; Xu N; Liu Q; Li Y; Liu Y; Wong H; Burt ME; Jossy SV; Han J; He Y
    Endocrinology; 2024 May; 165(7):. PubMed ID: 38815086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
    Kühnen P; Wabitsch M; von Schnurbein J; Chirila C; Mallya UG; Callahan P; Gnanasakthy A; Poitou C; Krabusch PM; Stewart M; Clément K
    Orphanet J Rare Dis; 2022 Feb; 17(1):38. PubMed ID: 35123544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Setmelanotide: First Approval.
    Markham A
    Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.
    Bischof JM; Van Der Ploeg LH; Colmers WF; Wevrick R
    Br J Pharmacol; 2016 Sep; 173(17):2614-21. PubMed ID: 27339818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanocortin signaling is decreased during neurotoxin-induced transient hyperphagia and increased body-weight gain.
    Dube MG; Pu S; Kalra SP; Kalra PS
    Peptides; 2000 Jun; 21(6):793-801. PubMed ID: 10958999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
    Kühnen P; Krude H; Biebermann H
    Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
    Yeo GSH; Chao DHM; Siegert AM; Koerperich ZM; Ericson MD; Simonds SE; Larson CM; Luquet S; Clarke I; Sharma S; Clément K; Cowley MA; Haskell-Luevano C; Van Der Ploeg L; Adan RAH
    Mol Metab; 2021 Jun; 48():101206. PubMed ID: 33684608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of early-onset obesity, hypocortisolism, and skin pigmentation problem due to a novel homozygous mutation in the proopiomelanocortin (POMC) gene in an Indian boy.
    Hung CN; Poon WT; Lee CY; Law CY; Chan AY
    J Pediatr Endocrinol Metab; 2012; 25(1-2):175-9. PubMed ID: 22570972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.